Indivior Pharmaceuticals Inc — News

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of [url="]Kahn Swick and Foti[/url], LLC (“KSF”) are investigating the propos

gurufocus.com - 2026-08-07 12:00:00

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Supernus Pharmaceuticals, Inc. (NasdaqGM: SUPN) to Indivior Pharmaceuticals, Inc. (Nasdaq: INDV). Under the terms of the proposed transaction, shareholders of Supernus will receive 1.5401 common shares of Indivior for each share of Supernus that they own. KSF is seeking to determine whether this con.

businesswire.com - 2026-08-07 11:21:00

Indivior announces a merger with Supernus to form a CNS-focused biopharma company, tops Q2 earnings and revenue estimates and raises its 2026 outlook.

zacks.com - 2026-08-04 13:21:09

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Indivior Pharmaceuticals, Inc. (NASDAQ: INDV) PR Newsw

gurufocus.com - 2026-08-03 16:00:00

NEW YORK, Aug. 3, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Indivior Pharmaceuticals, Inc. (NASDAQ: INDV ) related to its merger with Supernus Pharmaceuticals, Inc. Upon closing of the proposed transaction, Indivior shareholders will own approximately 56.5% of the combined company.

prnewswire.com - 2026-08-03 15:15:00

Supernus Pharmaceuticals (SUPN) has seen its stock rise following the announcement of an all-stock merger with Indivior (INDV). This strategic move comes alongs

gurufocus.com - 2026-08-03 12:14:00

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) and Indivior Pharmaceuticals Inc. (NASDAQ:INDV) on Monday agreed to unite through a tax-free all-stock merger of equals, forming a central nervous system (CNS) biopharmaceutical company.

benzinga.com - 2026-08-03 10:44:26

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Indivior Pharmaceuticals, Inc. (NASDAQ: INDV) and Supernus Pharmaceuticals, Inc. Upon closing of the Proposed Transaction, Indivior shareholders will own approximately 56.5% of the combined company.Halper Sadeh encourages Indivior shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpersa.

businesswire.com - 2026-08-03 10:44:00

Indivior Pharmaceuticals Inc. (INDV) came out with quarterly earnings of $1.15 per share, beating the Zacks Consensus Estimate of $0.97 per share. This compares to earnings of $0.51 per share a year ago.

zacks.com - 2026-08-03 08:46:03

Supernus Pharmaceuticals and Indivior Pharmaceuticals said on Monday they had agreed to an all-stock merger that ​would create a company with about $2.2 billion ‌in annual revenue and a portfolio of medicines for neurological, psychiatric and addiction-related conditions.

reuters.com - 2026-08-03 07:33:00

•   Q2'26 Total Net Revenue of $ 343 Million, Up 14% YoY •   Record Quarterly Total SUBLOCADE® Net Revenue of $ 253 Million in Q2'26, Up 21% YoY •   Record Quarterly GAAP Net Income of $122 Million and Record Non-GAAP Net Income of $142 Million in Q2'26 •   Record Quarterly Adjusted EBITDA of $ 186 Million in Q2'26, Up 111% YoY •   Repurchased Approximately 4.7 Million Shares in Q2'26 for $175 Million RICHMOND, Va., Aug. 03, 2026 (GLOBE NEWSWIRE) --  Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today reported its financial results for the second quarter ended June 30, 2026, and raised its full-year 2026 financial guidance.

globenewswire.com - 2026-08-03 06:31:00

RICHMOND, Va., July 23, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will report its second quarter 2026 financial results on Tuesday, August 4, 2026, at 7:00 a.m. U.S. EDT. Following the release of the financial results, Joe Ciaffoni, Chief Executive Officer, and other members of Indivior's leadership team will host a presentation via live webcast at 8:00 a.m. U.S. EDT.

globenewswire.com - 2026-07-23 10:00:00

Howard Marks hunts dislocation. His latest Oaktree 13F reveals five common-stock equity positions that look nothing like a bull-market portfolio: a leveraged turbo maker, the largest US gas producer bleeding YTD, a gold miner that just gave back a fifth of its price in three months, a tanker riding a geopolitical spike, and a specialty pharma with negative book value.

247wallst.com - 2026-07-21 10:32:27

Indivior Pharmaceuticals Inc. (INDV) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

zacks.com - 2026-06-29 09:56:14

Indivior, Aurinia, Ironwood, Altimmune and Marker have been highlighted in this Industry Outlook article.

zacks.com - 2026-06-26 06:01:05

Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, AUPH, IRWD, ALT and MRKR may prove to be good additions to one's portfolio.

zacks.com - 2026-06-25 09:41:16

Indivior, a leader in opioid dependence therapies, reported a notable insider sale following a year of exceptional share price gains.

fool.com - 2026-06-13 23:45:47

Long-acting injectable adoption remains low, but Indivior's market position, payer access and consumer campaign could help drive growth into 2026.

zacks.com - 2026-06-12 11:22:05

Indivior raised 2026 guidance after strong Q1 results, but investors are watching whether Sublocade growth and margin gains can sustain momentum.

zacks.com - 2026-06-12 11:16:12

Sublocade is powering Indivior's growth with record patient starts, rising volumes and a stable market share, setting up key demand tests for 2026.

zacks.com - 2026-06-12 11:16:12

INDV, RNW, LCUT, NTCT and TNK passed a screen for efficiency, outperforming industry peers on inventory, receivables, assets and margins.

zacks.com - 2026-06-02 09:20:55

Indivior develops buprenorphine-based treatments for opioid dependence, serving markets in the US, UK, and worldwide.

fool.com - 2026-05-30 16:01:06

Indivior develops buprenorphine-based therapies for opioid dependence, serving healthcare providers and treatment centers worldwide.

fool.com - 2026-05-30 14:57:39

RICHMOND, Va., May 20, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc., (Nasdaq: INDV) today announced findings from two new real-world evidence studies showing that adherence to extended-release buprenorphine, a monthly injectable commercially available as SUBLOCADE®, is associated with lower relapse risk, fewer infection-related complications, and reduced healthcare utilization among people living with opioid use disorder (OUD). “Collectively, these studies highlight the benefits of sustained treatment with monthly injectable buprenorphine, including reduced relapse risk and fewer serious complications that often drive acute care use,” said Christian Heidbreder, Ph.D., Chief Scientific Officer at Indivior. “These findings also emphasize the importance of proactively identifying patients at risk of treatment discontinuation and supporting continued access to evidence‑based medications for opioid use disorder.”

globenewswire.com - 2026-05-20 09:00:00

Indivior Pharmaceuticals Inc. (INDV) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

zacks.com - 2026-05-14 10:55:34

RICHMOND, Va., May 14, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will participate in the following upcoming investor conferences: 2026 Jefferies Global Healthcare Conference – New York, NY – June 3 rd Joe Ciaffoni, Chief Executive Officer, and Ryan Preblick, Chief Financial Officer, will host 1x1 / group meetings on Wednesday, June 3rd and will also participate in a fireside chat on Wednesday, June 3rd at 11:05 a.m.

globenewswire.com - 2026-05-14 07:00:00

Indivior develops proprietary treatments for opioid dependence, generating revenue from specialty pharmaceuticals across global markets.

fool.com - 2026-05-11 14:39:52